Oncology Flashcards

1
Q

The annual age-adjusted cancer incidence rates among men and women are decreasing for all of the following EXCEPT

A. Colorectal

B. Oropharynx

C. Lung

D. Thyroid

A

Answer: D

Incidence rates are declining for most cancer sites, but they are increasing among both men and women for melanoma of the skin, cancers of the liver and thyroid.

Incidence rates are decreasing for all four major cancer sites except for breast cancer in women.

(See Schwartz 10th cd., p. 274.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which of the following is NOT a hallmark of cancer?

A. Ability to invade and metastasize

B. Ability to evade apoptosis

C. Ability to evade autophagy

D. Ability to evade immune destruction

A

Answer: C

There are six essential alterations in cell physiology that dictate malignant growth:

1) self-sufficiency of growth signals,
2) insensitivity to growth-inhibitory signals,
3) evasion of apoptosis (programmed cell death), 4) potential for limitless replication,
5) angiogenesis, and
6) invasion and metastasis.

Recently, two additional hallmarks have emerged—reprogramming of energy metabolism and evading immune destruction.

(See Schwartz 10th ed., p. 277.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Characteristics of tumorigenic transformation of cells include which of the following?

A. Enhanced surface adherence

B. Monolayer confluence inhibition

C. Acquisition of chemoresistance

D. Immortalization

A

Answer: D

Abnormally proliferating, transformed cells outgrow normal cells in the culture dish (ie, in vitro) and commonly display several abnormal characteristics.

These include:

1) loss of contact inhibition (ie, cells continue to proliferate after a confluent monolayer is formed); 2) an altered appearance and poor adherence to other cells or to the substratum;
3) loss of anchorage dependence for growth;
4) immortalization; and
5) gain of tumorigenicity (ie, the ability to give rise to tumors when injected into an appropriate host).

(See Schwartz 10th ed., p. 277.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

The cell cycle includes all of the following phases EXCEPT

A. S phase

B. G1 phase

C. G2 phase

D. G3 phase

A

Answer: D

The cell cycle is divided into four phases. During the synthetic or S phase, the cell generates a single copy of its genetic material, whereas in the mitotic or M phase, the cellular components are partitioned between two daughter cells.

The G1 and G2 phases represent gap phases during which the cells prepare themselves for completion of the S and M phases, respectively.

When cells cease proliferation, they exit the cell cycle and enter the quiescent state referred to as G.

(Sec Schwartz 10th ed., p.279.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Which of the following factors is NOT suggestive of a hereditary cancer?

A. Tumor development at a younger than normal age.

B. Presence of bilateral disease.

C. Association with paraneoplastic syndrome.

D. Presence of multiple primary malignancies.

A

Answer: C

The following factors may suggest the presence of a hereditary cancer:

  1. Tumor development at a much younger age than usual.
  2. Presence of bilateral disease.
  3. Presence of multiple primary malignancies.
  4. Presentation of a cancer in the less affected sex (eg, male breast cancer).
  5. Clustering of the same cancer type in relatives.
  6. Occurrence of cancer in association with other conditions such as mental retardation or pathognomonic skin lesions.

(See Schwartz 10th ed., p. 287.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which of the following are associated with familial adenomatous polyposis (FAP)?

A. Osteomas

B. Glioblastoma multiforme

C. Meckel diverticulum

D. Esophageal atresia

A

Answer: A

Familial adenomatous polyposis (FAP) is associated with benign extracolonic manifestations that may be useful in identifying new cases, including congenital hypertrophy of the retinal pigment epithelium, epidermoid cysts, and osteomas.

In addition to colorectal cancer, patients with FAP are at risk for upper intestinal neoplasms (gastric and duodenal polyps, duodenal and periampullary cancer), hepatobiliary tumors (hepatoblastoma, pancreatic cancer, and cholangiocarcinoma), thyroid carcinomas, desmoid tumors, and medulloblastomas.

(See Schwartz 10th ed., p. 291.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Which mutated gene malignant disease association is correct

A. PTEN and Li-Fraumeni syndrome

B. RET and MEN2 syndrome

C. P16 and synovial sarcoma

D. BRCA1 and adrenocortical carcinoma

A

Answer: B

MEN2 syndrome is caused by gain of function mutations in the RET gene.

Li-Fraumeni syndrome is associated with mutation of TP53.

Mutations in p16 is associated with melanomas, as well as cancers of the pancreas, esophagus, head and neck, stomach, breast, and colon.

BRCA1 is associated with breast and ovarian carcinoma. (See Schwartz 10th ed., pp. 291-293.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Risk for invasive breast cancer development is increased for each factor EXCEPT

A. Age at menarche <12.

B. Age at first live birth >30.

C. Biopsy-proven atypical hyperplasia.

D. No previous breast biopsy.

A

Answer: D

Risk factors for the development of breast cancer is summarized in Table 10-1.

Previous breast biopsies are associated with an increase in risk of invasive breast cancer.

No previous breast biopsy confers the baseline risk. (See Schwartz 10th ed., Table 10-8, p. 297.)

Relative Risk(%)
Risk Factor
Age at menarche (years)
>14 RR = 1.00

12-13 RR = 1.10

<12 RR = 1.21

Age at first live birth (years)
Patients with no frst-degree relatives with cancer
<20 RR = 1.00

20-24 RR = 1.24

25-29 or nulliparous RR =1.55

> 30 RR = 1.93

Patients with one first-degree-relative with cancer
<20 RR = 1.00

20-24 RR = 2.64

25-29 or nulliparous RR = 2.76

> 30 RR = 2.83

Patients with >2 first-degree relatives
with cancer

<20 RR = 6.80

20-24 RR = 5.78

25-29 or nullipatous RR = 4.91

> 30 RR = 4.17

Breast biopsies (number)
Patients aged <50 at counseling
0 RR = 1.00

1 RR = 1.70

> 2 RR = 2.88

Patients aged >50 at counseling

0 RR = 1.00

1 RR = 127

> 2 RR = 1.62

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Routine ongoing cancer screening is recommended for which of the following malignancies?

A. Ovary

B. Leukemia

C. Carcinoma of the kidney

D. Sarcoma

A

Answer: A

On the occasion of a periodic health examination, the cancer-related checkup should include examination for cancers of the thyroid, testicles, ovaries, lymph nodes, oral cavity, and skin, as well as health counseling about tobacco, sun exposure, diet and nutrition, risk factors, sexual practices, and environmental and occupational exposures. (See Schwartz 10th ed., p. 299.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Depending on the tumor, acceptable approaches to biopsy include any of the following EXCEPT

A. Fine-needle aspiration

B. Core needle biopsy

C. Incisional biopsy

D. Morcellation

A

Answer: D

A sample of a lesion can be obtained with a needle or with an open incisional or excisional biopsy specimen.

Core biopsy specimen, such as fine-needle aspiration, is relatively safe and can be performed either by direct palpation (eg, a breast mass or a soft tissue mass) or can be guided by an imaging study (eg, stereotactic core biopsy specimen of the breast).

Open biopsy specimens have the advantage of providing more tissue for histologic evaluation and the disadvantage of being an operative procedure.

Incisional biopsy specimens are reserved for very large lesions in which a definitive diagnosis cannot
be made by needle biopsy specimen.

Excisional biopsy specimens are performed for lesions for which either core biopsy specimen is not possible or the results are nondiagnostic.

(See Schwartz 10th ed.,p. 300.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Anticancer chemotherapy agents include all of the following EXCEPT

A. Alkylating agents

B. Antitumor antibiotics

C. Prometabolites

D. Plant alkaloids

A

Answer: C

Anticancer agents include alkylating agents, antitumor antibiotics, antimetabolites, and plant alkaloids.

Antimetabolites are cell-cycle specific agents that have their major activity in the S phase of the cell cycle.

These drugs are most effective in tumors that have a high growth fraction, and include folate antagonists, purine antagonists, and pyrimidine antagonists.

(See Schwartz 10th cd., p. 307.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Approved strategies for cancer chemoprevention include all of the following EXCEPT

A. Neurontin for malignant peripheral nerve sheath tumor

B. Tamoxifen for breast cancer

C. Celecoxib for FAP syndrome

D. 13-cis-retinoic acid for oral leukoplakia

A

Answer: A

The systemic or local administration of therapeutic agents to prevent the development of cancer, called chemoprevention, is being actively explored for several cancer types.

In breast cancer, the NSABP Breast Cancer Prevention Trial demonstrated that tamoxifen administration reduces the risk of breast cancer by one-half and reduces the risk of estrogen receptor-positive tumors by 69% in high-risk patients.

Therefore, tamoxifen has been approved by the FDA for breast cancer chemoprevention.

The subsequent NSABP P-2 trial demonstrated that raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and is associated with a lower risk of thromboembolic events and cataracts but a non-statistically significant higher risk of noninvasive breast cancer; these findings led the FDA to approve raloxifene for prevention as well.

Several other agents are also under investigation. Celecoxib has been shown to reduce polyp number and polyp burden in patients with FAP, which led to its approval by the FDA for these patients.

In head and neck cancer, 13-cis-retinoic acid has been shown both to reverse oral leukoplakia and to reduce second primary tumor development.

(See Schwartz 10th ed., p.315.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

A recently identified cell alterations that denote malignancy:

A. Cytoplasmic degeneration

B. Reprogramming of energy metabolism and evasion of immune destruction

C. Nuclear multiplication

D. Mitochondrial fusion

A

B. Reprogramming of energy metabolism and evasion of immune destruction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

The normal cellular genes that contribute to cancer when abnormal are:

A. Proto-oncogene

B. Oncogenes

C. Mutation factor

D. Carcinogen

A

B. Oncogenes

Oncogenes are normal cellular genes that contribute to cancer when abnormal.

Proto-oncogene is the precursor gene.

They can be growth factors (PDGF), growth factor receptors (HER2), intracellular signal transduction molecules (ras), nuclear transcription factors (c-myc).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Chemotherapy destroys cells by first order kinetics, meaning that with the administration of certain anticancer drug:

A. All cancer cells are killed by the drug

B. Constant percentage of cells are killed

C. Constant number of cells are killed

D. Constant percentage and number of cells are killed

A

B. Constant percentage of cells are killed

First-order kinetics: with administration of a drug, a CONSTANT PERCENTAGE of cells are killed, and not a constant number.

The rate of elimination is proportional to the drug concentration.

If a patient has 1kg load of tumor cells, administration of the drug results in (3-log cell kill): 1kg –> 1g

If treated with another dose (another decrease of 3-log cell kill): 1g –> 1mg rather than being eliminated totally.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Which of the following is a prognostic marker?

A. Her-2-neu

B. PSA

C. CEA

D. AFP

A

A. Her-2-neu

  • Epidermal growth factor receptor family
  • Tyrosine kinase
  • Overexpression leads to increase in cell proliferation and resistance to pro-apoptotic stimuli
  • Role in cancer biology has been leveraged for therapeutics
17
Q

Which of the following is not true of radiation therapy?

A. Radiation results in DNA damage by single and double strand breaks in the DNA backbone

B. The most radiosensitive phase of cell division are G1 and the late S phases

C. Generally, hypoxic cells are significantly less radiosensitive than aerated cells

D. Radiation damage is manifested primarily by the loss of cellular reproductive integrity

A

B. The most radiosensitive phase of cell division are G1 and the late S phases

  • Radiation deposition results in DNA damage manifested by single and double stranded breaks in the sugar phosphate backbone of the DNA molecule.
  • Manifested primarily by loss of cellular reproductive integrity.
  • Hypoxic cells are significantly less radiosensitive than aerated cells.
  • The most radiosensitive phases are G2 and M phases.
  • Whereas G1 and S phases are less sensitive
  • FRACTIONATION allows the surviving cells in the G1 and S phase to progress to more sensitive phases.
18
Q

Which of the following cancer-tumor marker pairing or association is false?

A. Prostate cancer - PSA

B. Pancreatic cancer - CA 19-9

C. Colonic cancer - CEA

D. Breast cancer - ER, PR

A

D. Breast cancer - ER, PR

PSA

  • Androgen regulated serine protease produced by the prostate epithelium.
  • Shown useful in evaluating the effectiveness of treatment for prostate cancer and monitoring recurrence after therapy.

Carcinoembryonic Antigen (CEA)

  • Glycoprotein found in the embryonic endodermal epithelium
  • Elevated levels have been detected in patients with primary colorectal cancer as well as breast, lung, ovary, prostate, liver and pancreas.
  • Used in monitoring for recurrence or progression of colon cancer in patients after treatment.
  • Data are stronger in its use for monitoring for postoperative recurrences.
  • Marker of choice for monitoring metastatic colorectal cancer during systemic therapy.

Cancer Antigen 19-9

  • Elevations in serial examination during chemotherapy for pancreatic cancers may indicate progression
  • Usually measured every 1-3 months during active therapy.
19
Q

Malignant cells are cells that do not enter which phase of the cell cycle?

A. S-phase

B. G1 Phase

C. G0 Phase

D. M Phase

A

C. G0 Phase

Cell Cycle
- 4 phases (S, M, G1, G2)

  • S phase (Synthetic): cell generates a single copy of its genetic material
  • M phase (Mitotic): cellular components are partitioned between two daughter cells
  • G1 and G2 phases: represents gap during which the cells prepare for S & M phases respectively
  • G0 phase: when the cell exits the cycle and enters a quiescent state (bypassed by tumor cells; they proceed to repeated cell proliferation)
20
Q

The goal for surgical therapy for cancer is to achieve oncologic cure. This would include?

A. Resection of primary tumor with negative margins

B. En bloc removal of the draining lymphatics

C. Metastasectomy in selected patients

D. All of the above

A

D. All of the above

21
Q

Selected viral carcinogen include the following except:

A. Epstein Barr virus

B. Hepatitis A virus

C. HIV Type 1

D. HPV Type 16 and 18

A

B. Hepatitis A virus

EBV

  • Burkitt’s lymphoma
  • Hodgkin’s disease
  • Immunosuppression-related lymphoma
  • Nasopharyngeal carcinoma

Hepatitis B and C Virus
- Hepatocellular carcinoma

HIV Type 1 Virus

  • Kaposi’s sarcoma
  • Non-Hodgkin’s lymphoma

HPV Type 16 & 18

  • Cervical cancer
  • Anal cancer
22
Q

True of lymph node mapping and sentinel LN biopsy EXCEPT?

A. Alternative care for the management of melanoma and breast cancer

B. Identify and remove the LN most likely to contain mets

C. Avoid morbidity of LN dissection on node negative patients

D. Lymphatic mapping is done using isosulfan blue dye, technetium labelled sulfur colloid or albumin

A

A. Alternative care for the management of melanoma and breast cancer

SLNB

  • First performed on penile cancer by Cabanas
  • Standard of care for management of melanomas and breast cancers after resection of the primary tumor
  • First node to receive drainage from the tumor site
  • Avoids morbidity of lymph node dissection in node-negative patients
  • Lymphatic mapping is performed using isosulfan blue dye or technetium-labelled sulfur colloid or albumin

SLNB in Breast CA

  • ACOSOG Z11
  • Positive SLNB will be followed by a full axillary dissection
  • BCT with whole breast irradiation
  • Overall survival and Disease-free survival
  • 5-year OS: 91.8% (with ALN) vs. 92.5% (SLN alone)
  • 5-year DFS: 82.2% (with ALN) vs. 83.9% (SLN alone)

SLNB in Melanoma

  • 5-40% of patients undergoing SLNB will be upstaged from clinical stage I-II to pathologic stage III (based on subclinical micrometastasis)
  • Low probability of finding a positive node in melanomas <1mm thin
  • Prospective data from MSLT-1 for melanomas >1.2mm thick, SLN status was the strongest predictor of DFS
  • Among patients with (+) SLN, SLN burden (# of positive SLN) is a prognostic factor for recurrence and survival
  • Therapeutic value: SLNB did not improve Disease-Specific Survival (DSS) compared with nodal basin observation alone, regardless of lesion thickness
  • SLNB did improve DFS in intermediate (1.2-3.5mm) 7% and thick (>3.5mm) 10%
23
Q

Which of the ff malignancies does histologic grade correlate with prognosis?

A. Melanoma

B. Colon cancer

C. Hepatocellular cancer

D. Soft tissue sarcoma

A

D. Soft tissue sarcoma

Prognosticating factors:
Melanoma: LYMPH NODE STATUS

Colorectal Cancer: LYMPH NODE STATUS, PERINEURAL INVASION

Hepatocellular Cancer: CLINICAL STAGE, RATE OF TUMOR GROWTH, GENERAL HEALTH OF THE PATIENT, LIVER FUNCTION, TREATMENTS ADMINISTERED

Sarcoma: HISTOLOGIC GRADE

24
Q

Which of the following is not true of drug resistance in cancer therapy?

A. According to the gompertzian model, the exponential growth phase causes smaller tumors to be more chemosensitive

B. Kinetic resistance is permanent and maintaining drug level will not make cells vulnerable to the drug

C. Pharmacologic resistance occurs due to insufficient drug concentration

D. Cancer cells acquire resistance upon prolonged treatment with targeted therapy through loss of the target

A

B. Kinetic resistance is permanent and maintaining drug level will not make cells vulnerable to the drug

INTRINSIC & ACQUIRED DRUG RESISTANCE

GOMPERTZIAN MODEL
Cancer cells grow rapidly (exponential growth phase) then slow down due to hypoxia and decreased nutrient supply.

KINETIC RESISTANCE
Cells may exhibit reduced sensitivity to drug by virtue of their cell-cycle distribution. If the drug levels can be maintained, all cells will eventually pass through the vulnerable phase of the cell cycle.

PHARMACOLOGIC RESISTANCE: Failure to kill cells due to insufficient drug concentration.

25
Q

True of combination chemotherapy:

A. It prevents or delays the emergence of drug resistant cell lines

B. It provides maximum cell kill with the range of toxicity for each drug that can be tolerated by the host

C. It offers a broader range of coverage of resistant cell lines

D. All of the above

A

D. All of the above

COMBINATION CHEMOTHERAPY

  • Combining cell-cycle-specific and cell-cycle-nonspecific agents is advantageous
  • E.g. Docetaxel (cell-cycle specific) + Cyclophosphamide (cell-cycle nonspecific)
  • Drugs with different pattern of resistance are also best combined to minimize cross-resistance
  • Treatment-free interval between cycles is kept to the shortest possible time that will allow recovery of normal tissues.
26
Q

True about radiation therapy except:

A. Radiation therapy is usually given immediately after surgery to minimize local recurrence

B. Preoperative radiation therapy minimizes tumor seeding during surgery

C. IMRT is a complex radiologic technique which delivers radiation preferentially to target structures while minimizing dose to adjacent normal structures

D. Radiation injury during abdominal and pelvic irradiations are due to decreased mobility of small bowel loops

A

A. Radiation therapy is usually given immediately after surgery to minimize local recurrence

RT PLANNING

  • Done through a process called simulation
  • Conventional fractionation is 1.8-2 Gy/day, administered 5 days/week for 3-7 weeks.
  • Goal of RT is to decrease a local-regional recurrence rate.
  • Preoperative RT decreases tumor seeding during surgery and it allows for smaller field of treatment.
  • Disadvantage: Affects wound healing.
  • Usually given 3-4 weeks postoperatively to allow healing.
  • Post-laparotomy adhesions may decrease the mobility of small bowel loops, increasing the risk for injury during abdominal and pelvic irradiation.
  • Chemotherapy before RT decreases tumor burden, which facilitates RT.